Background. Hip resurfacing arthoplasty (HRA) showed promising early and mid-terms results at the beginning of the new millennium. Adverse local tissue reactions associated with metal debris considerably slowed down the implantation of HRA which use is now limited to a few specialized centers. The long term success of this procedure, however, is still largely unknown. This study aimed to provide the clinical results of a series of 400 consecutive HRA with a minimum follow-up of 20 years. Methods. All patients treated with Conserve. ®. Plus HRA between November 1996 and November 2000 were retrospectively selected and 355 patients (400 hips) were included. The clinical results of this series was previously reported in 2004 at a follow up of 2 to 6 years[1]. There were 96 women (27%) and 259 men (73%). Mean age at surgery was 48.2 ± 10.9 years. Long-term survivorship was assessed with Kaplan-Meier survival estimates. UCLA hip scores and SF-12 quality of life scores were collected at follow-up visits. Radiographic positioning of the acetabular component was assessed with the computation of the contact patch to rim (CPR) distance. Radiolucencies about the metaphyseal stem and around the acetabular component were recorded to assess the quality of the component fixation. Results. The mean time of follow up was 16.3 ± 5.5 years including 183 hips beyond 20 yrs. Nine hips were lost to follow up (2.2%) Thirty-three patients (35 hips,8.8%) died of causes unrelated to the surgery at a mean 11.9 ± 5.3 years after surgery The mean UCLA hip scores at last follow-up were 9.3 ± 1.0, 9.1 ± 1.4, 9.0 ± 1.8, and 6.9 ± 1.7 for pain, walking, function, and activity, respectively. Post-operative SF-12 scores were 48.4 ± 10.3 for the physical component and 48.5 ± 15.5 for the mental component and did not differ from those of the general US population. Fifty-five patients (60 hips) underwent revision surgery at a mean time of 9.3 ± 5.8 years. Indications for revision surgery included acetabular component loosening (12 hips), femoral component loosening (31 hips), femoral neck fracture (6 hips), wear (6 hips), sepsis (2 hips), recurrent dislocations (1 hip), acetabular component protrusion after over-reaming (1 hip) and unknown (1 hip which was revised in another center). Using any revision as an endpoint, the Kaplan-Meier survivorship was 95.2% at 5 years, 91.2% at 10 years, 87.3% at 15 years, and 83.2% at 20 years. A multivariate model for risk factor analysis showed a diagnosis of developmental dysplasia (p=0.020) and a low body mass index (typically associated with higher levels of activity) (p=0.032), to be significantly related to revision for any reason. Female sex was not a risk factor after adjustment for hip dysplasia and component size was made (Table 1). There was only 1 femoral failure (a late neck fracture 19 years after surgery) among the hips reconstructed with a cemented metaphyseal stem (n=59). Five of the 6 hips (1.5%) with wear-related failures all had mal-positioned sockets (CPR distance <10mm) and were therefore preventable. There were no cases with a high score of aseptic lymphocytic vasculitis-associated lesions (ALVAL)[2], suggesting metal sensitivity. X-ray analysis showed excellent persisting fixation in all but one hip. Conclusions. In this group of patients operated over 20 years ago, HRA keeps providing excellent pain relief and quality of life to the patients. Subsequent progress in the preparation of the femoral head has considerably reduced the failure rate on the femoral side which was the main mode of failure in this initial series[3, 4]. The 83.1% 20 year survivorship of this initial series surpasses that of total hip arthroplasties in use 20 years ago in this young patient population[5]. Life-long durability of the device is anticipated for most of the remaining patients. The established benefits of this procedure, such as a low dislocation rate, an anatomic reconstruction with physiologic loading of the proximal femur, the absence of taper corrosion, and an easy conversion if ever necessary, make HRA a preferable alternative to THA in young and active patients. For any figures, tables, or references, please contact the authors directly

Introduction. Modularity in femoral stem designs allow surgeons to independently control leg length, offset, and femoral version in revision or complex primary THA cases. Initial enthusiasm in these modular stems has been tempered by recognition of modular junction failures. This study evaluates mean 5-year clinical results and survival rates of a 3-part titanium alloy modular femoral implant with unique taper geometries and a metaphyseal plasma spray surface. The current results are presented after pre-market independent fatigue testing performed by Orthopaedic Laboratory (Greenwald) and previously published early clinical results in 2006. Low plasticity burnishing (LPB) was added in 2005 to further strengthen the neck metaphyseal modular junction. The modular stem component is a polished cylindrical splined clothespin design. Our hypothesis is that these unique modular junctions succeed in offering the advantages of modularity without failure at this midterm follow-up period. Methods. Between May 2010 and July 2016, 32 total hip arthroplasties were performed using a 3-part femoral stem with neck-metaphyseal-stem modular junctions. Surgeries were either the final stage of a two-stage revision for infection, revision THR for loosening, or a revision of a previous non-prosthetic replacement procedure. Patients were entered into an IRB-approved registry and followed with x-rays, HHS, Oxford scores, and patient satisfaction scores. Patients who failed to return for routine follow-up were contacted by phone or email. Two patients had died with their implants intact. Six patients could not be reached for an updated follow-up. One stem was revised for loosening at 33 months due to failed osseointegration in a patient with chronic renal failure. This removed stem was submitted for taper exam and sectioning. Results. There were 23 patients for evaluation at a mean 61 months (range 21–98). Mean patient age at implantation was 56 (range 25–88), BMI was 27 (range 20–40). There were no modular junction failures. Modular junctions examined in the retrieved implant did not demonstrate any abnormalities other than normal wear properties. HHS and OHS scores both improved between pre-op and final follow-up, 23 to 85 and 17 to 43, respectively. Average patient satisfaction score at final follow-up was 9.8 out of 10 (min 8, max 10). Radiographic examination showed stem subsidence > 2mm and radiolucencies around the metaphyseal cone in 1 patient, the same patient who required implant removal. Radiolucencies were seen along the polished stem tip in 43% of cases, spot welding at the distal metaphyseal cone in 67% of cases, and mild proximal-medial stress shielding in 33% of cases. Conclusion. This unique 3-part modular stem with metaphyseal fixation shows good functional and radiographic results at 5-year follow-up. There were no junctional failures. One stem was removed due to failure to osseointegrate and showed no worrisome taper abnormalities. Spot welding is common around the plasma spray metaphyseal cone. Implant removal, if necessary, only requires disruption of the metaphyseal fixation. Further follow-up will be important to confirm our confidence in this unique stem design

Aims

The purpose of this study is to report our updated results at a minimum follow-up of 30 years using a first generation uncemented tapered femoral component in primary total hip arthroplasty (THA).

We followed the first 354 consecutive implantations of a cementless, double-tapered straight femoral stem in 326 patients. Follow-up was at a mean of 12 years (10 to 15). The mean age of the patients was 57 years (13 to 81). At follow-up, 56 patients (59 hips) had died, and eight (eight hips) had been lost to follow-up. Twenty-five hips underwent femoral revision, eight for infection, three for periprosthetic fracture and 14 for aseptic loosening. The overall survival was 92% at 12 years (95% CI 88 to 95). Survival with femoral revision for aseptic loosening as an endpoint was 95% (95% CI 92 to 98). The median Harris hip score at follow-up was 84 points (23 to 100). Radiolucent lines (< 2 mm) in Gruen zones 1 and 7 were present in 38 (16%) and 34 hips (14%), respectively. Radiolucencies in zones 2 to 6 were found in five hips (2%). The results for mid- to long-term survival with this femoral component are encouraging and compare with those achieved in primary cemented total hip arthroplasty. The high rate of loosening of the cup and the high rate of pain are, however, a source of concern

The Alloclassic and Endoplus femoral stems have the same grit-blasted surface and are hot forged from the same titanium alloy. Only the external form of the implants differs slightly. It was our aim to examine the differences in radiographic bone response between the Alloclassic (second generation) and the Endoplus (third generation) femoral stems. We compared 79 prostheses in 70 matched patients studied over a minimum of two years. Radiolucent lines, adaptive bone remodelling, subsidence, heterotopic bone formation and lysis were recorded in the Gruen zones. Radiolucencies were mainly found in zones 1 and 7 but to a greater extent in the Endoplus than in the Alloclassic group (p < 0.001 in zone 1, p < 0.05 in zone 7). We found lucent lines in three or more Gruen zones in seven patients all of whom were in the Endoplus group (p < 0.05). Zones 2 and 6 had a significantly higher rate of lucencies in the Endoplus group (p < 0.001). We encountered a combination of proximal lucent lines in zones 1 and 7 with distal hypertrophy of the cortical bone in zones 2, 3, 5 and 6 in eight patients, all from the Endoplus group (p < 0.05). In other patients bone atrophy (stress shielding) in zones 2 and 6 was seen more frequently in the Endoplus than in the Alloclassic group (p < 0.001). In neither group was there radiological evidence of osteolysis. Heterotopic bone formation and subsidence occurred with similar frequency in both groups. Our study shows that a small change in the form of the femoral implant can result in statistically significant radiological changes in bone remodelling. Whether this will result in clinical compromise is unknown. However, it seems likely that the Endoplus femoral stem will perform differently from the Alloclassic

Aims

We present the clinical and radiological results at a minimum follow-up of 20 years using a second-generation uncemented total hip arthroplasty (THA). These results are compared to our previously published results using a first-generation hip arthroplasty followed for 20 years.

Aims

We aimed to investigate if the use of the largest possible cobalt-chromium head articulating with polyethylene acetabular inserts would increase the in vivo wear rate in total hip arthroplasty.

Aims

Adverse local tissue reactions associated with abnormal wear considerably slowed down the general use of metal-on-metal (MoM) hip resurfacing arthroplasty (HRA), now limited to a few specialized centres. In this study, we provide the clinical results of 400 consecutive MoM HRAs implanted more than 20 years ago in one such centre.

Aims

To investigate the longevity of uncemented fixation of a femoral component in total hip arthroplasty (THA) in patients with Dorr type C proximal femoral morphology.

We conducted a retrospective study to assess the prevalence of adverse reactions to metal debris (ARMD) in patients operated on at our institution with metal-on-metal (MoM) total hip replacements with 36 mm heads using a Pinnacle acetabular shell. A total of 326 patients (150 males, 175 hips; 176 females, 203 hips) with a mean age of 62.7 years (28 to 85) and mean follow-up of 7.5 years (0.1 to 10.8) participating in our in-depth modern MoM follow-up programme were included in the study, which involved recording whole blood cobalt and chromium ion measurements, Oxford hip scores (OHS) and plain radiographs of the hip and targeted cross-sectional imaging. Elevated blood metal ion levels (> 5 parts per billion) were seen in 32 (16.1%) of the 199 patients who underwent unilateral replacement. At 23 months after the start of our modern MoM follow-up programme, 29 new cases of ARMD had been revealed. Hence, the nine-year survival of this cohort declined from 96% (95% CI 95 to 98) with the old surveillance routine to 86% (95% CI 82 to 90) following the new protocol. Although ARMD may not be as common in 36 mm MoM THRs as in those with larger heads, these results support the Medicines and Healthcare Products Regulatory Agency guidelines on regular reviews and further investigations, and emphasise the need for specific a follow-up programme for patients with MoM THRs.

Cite this article: Bone Joint J 2014; 96-B:1610–17.

We reviewed 123 second-generation uncemented total hip replacements performed on 115 patients by a single surgeon between 1993 and 1994. The acetabular component used in all cases was a fully porous-coated threaded hemispheric titanium shell (T-Tap ST) with a calcium ion stearate-free, isostatically compression-moulded polyethylene liner. The titanium femoral component used was a Taperloc with a reduced distal stem. No patient was lost to follow-up. Complete clinical and radiological follow-up was obtained for all 123 hips at a mean of 14 years (12 to 16). One femoral component was revised after a fracture, and three acetabular components for aseptic loosening. No additional femoral or acetabular components were judged loose by radiological criteria. Mild proximal femoral osteolysis was identified in two hips and minor acetabular osteolysis was present in four. The mean rate of penetration of the femoral head was 0.036 mm/year (0.000 to 0.227).

These findings suggest that refinements in component design may be associated with excellent long-term fixation in cementless primary total hip replacement.

Aims

The widely used and well-proven Palacos R (a.k.a. Refobacin Palacos R) bone cement is no longer commercially available and was superseded by Refobacin bone cement R and Palacos R + G in 2005. However, the performance of these newly introduced bone cements have not been tested in a phased evidence-based manner, including roentgen stereophotogrammetric analysis (RSA).

We studied a consecutive series of 285 uncemented total hip replacements in 260 patients using the Taperloc femoral component and the T-Tap acetabular component. The outcome of every hip was determined in both living and deceased patients. A complete clinical and radiological follow-up was obtained for 209 hips in 188 living patients, followed for a mean of 14.5 years (10 to 18.9). They were divided into two groups, obese and non-obese, as determined by their body mass index. There were 100 total hip replacements in 89 patients in the obese cohort (body mass index ≥ 30 kg/m²), and 109 in 99 non-obese (body mass index < 30 kg/m²) patients. A subgroup analysis of 31 patients of normal weight (body mass index 20 kg/m² to 25 kg/m²) (33 hips) and 26 morbidly obese patients (body mass index ≥ 35 kg/m²) (30 hips) was also carried out.

In the obese group five femoral components (5%) were revised and one (1%) was loose by radiological criteria. Femoral cortical osteolysis was seen in eight hips (8%). The acetabular component was revised in 57 hips (57%) and a further 17 (17%) were loose. The mean Harris hip score improved from 52 (30 to 66) pre-operatively to 89 (49 to 100) at final follow-up. Peri-operative complications occurred in seven patients (7%).

In the non-obese group six (6%) femoral components were revised and one (1%) was loose. Femoral cortical osteolysis occurred in six hips (6%). The acetabular component was revised in 72 hips (66%) and a further 18 (17%) were loose. The mean Harris hip score increased from 53 (25 to 73) prior to surgery to 89 (53 to 100) at the time of each patient’s final follow-up radiograph.

No statistically significant difference was identified between the obese and non-obese patients with regards to clinical and radiological outcome or complications. The subgroup analysis of patients of normal weight and those who were morbidly obese showed no statistically significant difference in the rate of revision of either component.

Our findings suggest there is no evidence to support withholding total hip replacement from obese patients with arthritic hips on the grounds that their outcome will be less satisfactory than those who are not obese.

Between December 2004 and June 2006, 136 patients (156 total hip replacements), were sent from the waiting list of the Cardiff Vale NHS Trust to the NHS Treatment Centre, Weston-super-Mare, in an attempt to reduce the waiting time for total hip replacement. Because of concerns about their outcome, each patient was contacted and invited to attend a review appointment with a consultant specialising in hip and revision hip replacement.

A total of 98 patients (113 hips) were reviewed after a mean of 23 months (11 to 30). There were 104 cemented hips, seven hybrid and two cementless. An acetabular inclination of > 55° was seen in 18 (16%). Radiolucent lines around the acetabular component were seen in 76 (67%). The femoral component was in more than 4° of varus in 47 (42%). The medial floor had been breached in 13 (12%) and there was a leg-length discrepancy of more than 1 cm in ten (9%). There were three dislocations, one femoral fracture, one pulmonary embolus, one deep infection and two superficial wound infections.

To date, 13% (15 hips) have been revised and a further 4% (five hips) await revision, mostly for a painful loose acetabular component. The revision rate far exceeds the 0.5% five-year failure rate reported in the Swedish Registry for the components used. This initiative and the consequent need for correction of the problems created, has significantly increased the workload of our unit.

Few independent studies have reported the outcome of resurfacing arthroplasty of the hip. The aim of this study was to report the five-year clinical outcome and seven-year survival of an independent series.

A total of 610 Birmingham Hip Resurfacing arthroplasties were performed in 532 patients with a mean age of 51.8 years (16.5 to 81.6). They were followed for between two and eight years; 107 patients (120 hips) had been followed up for more than five years. Two patients were lost to follow-up. At a minimum of five years’ follow-up, 79 of 85 hips (93%) had an excellent or good outcome according to the Harris hip score. The mean Oxford hip score was 16.1 points (sd 7.7) and the mean University of California Los Angeles activity score was 6.6 points (sd 1.9). There were no patients with definite radiological evidence of loosening or of narrowing of the femoral neck exceeding 10% of its width. There were 23 revisions (3.8%), giving an overall survival of 95% (95% confidence interval 85.3 to 99.2) at seven years. Fractured neck of femur in 12 hips was the most common indication for revision, followed by aseptic loosening in four. In three hips (three patients) (0.5%), failure was possibly related to metal debris.

Considering that these patients are young and active these results are good, and support the use of resurfacing. Further study is needed to address the early failures, particularly those related to fracture and metal debris.

We describe a new technique of reconstruction of the deficient acetabulum in cementless total hip arthroplasty. The outer iliac table just above the deficient acetabulum is osteotomised and slid downwards. We have termed this an iliac sliding graft. Between October 1997 and November 2001, cementless total hip arthroplasty with an iliac sliding graft was performed on 19 patients (19 hips) with acetabular dysplasia. The mean follow-up was 3.4 years (2 to 6).

The mean pre-operative Harris hip score was 45.1 which improved significantly to 85.3 at the time of the final follow-up. No patient had post-operative abductor dysfunction. Incorporation of the graft was seen after two to three months in all patients. Resorption of the graft and radiolucencies were infrequent. This technique is a useful alternative to femoral head autografting when the patient’s own femoral head cannot be used.

We report the clinical and radiological outcome of 86 revisions of cemented hip arthroplasties using JRI-Furlong hydroxyapatite-ceramic-coated acetabular and femoral components. The acetabular component was revised in 62 hips and the femoral component in all hips. The mean follow-up was 12.6 years and no patient was lost to follow-up.

The mean age of the patients was 71.2 years. The mean Harris hip and Oxford scores were 82 (59 to 96) and 23.4 (14 to 40), respectively. The mean Charnley modification of the Merle d’Aubigné and Postel score was 5 (3 to 6) for pain, 4.9 (3 to 6) for movement and 4.4 (3 to 6) for mobility. Migration of the acetabular component was seen in two hips and the mean acetabular inclination was 42.6°. The mean linear polyethylene wear was 0.05 mm/year. The mean subsidence of the femoral component was 1.9 mm and stress shielding was seen in 23 (28%) with bony ingrowth in 76 (94%). Heterotopic ossification was seen in 12 hips (15%). There were three re-revisions, two for deep sepsis and one for recurrent dislocation and there were no re-revisions for aseptic loosening. The mean EuroQol EQ-5D description scores and health thermometer scores were 0.69 (0.51 to 0.89) and 79 (54 to 95), respectively. With an end-point of definite or probable loosening, the probability of survival at 12 years was 93.9% and 95.6% for the acetabular and femoral components, respectively. Overall survival at 12 years, with removal or further revision of either component for any reason as the end-point, was 92.3%.

Our study supports the continued use of this arthroplasty and documents the durability of hydroxyapatite-ceramic-coated components.